Navigation Links
NexBio Presents Data at ACAAI 2010 Demonstrating Mechanism of Action for Improvement in Airway Function by DAS181 (Fludase®*)
Date:11/11/2010

SAN DIEGO, Nov. 11, 2010 /PRNewswire/ -- NexBio, Inc. announced the presentation of new data at the 2010 annual American College of Allergy, Asthma, and Immunology in Phoenix, Arizona.  The presentation was entitled "DAS181 (Fludase®), a Sialidase, Decreases Airway Resistance by Modulating Muscarinic Receptor Signaling."

DAS181 (Fludase®) is an investigational broad spectrum host-targeting antiviral drug candidate undergoing clinical development for the treatment and prevention of Influenza-Like Illness caused by all strains of influenza and parainfluenza (PIV).  These new data show that, independent of its antiviral activity, and by a different mechanism of action, DAS181 may have benefit for airway diseases such as asthma and COPD.

NexBio presented nonclinical data at ACAAI 2009 from studies in three animal models of asthma, demonstrating that DAS181 inhibits airway hyperreactivity characteristic of asthma, as well as airway inflammatory cells and airway mucus, characteristic of chronic airway inflammatory conditions such as COPD.  The current presentation at 2010 ACAAI builds on this prior work by elucidating a key mechanism of action.  The data demonstrate that desialylation of airway muscarinic receptors in both in vivo and in vitro models unexpectedly reduces muscarinic pathway signaling. DAS181 given to mice once daily for three days, at doses lower than those used for antiviral treatment, leads to significantly reduced airway resistance in response to challenge by methacholine.

"The data suggest that DAS181 may have a dual benefit for patients with airway disease who become infected with the respiratory viruses influenza and parainfluenza, as DAS181 may fight infection while simultaneously controlling the underlying airway disease.  These patients are at high risk for exacerbations of their airway disease, as was seen during the 2009 Pandemic, and it is possible that DAS181 may l
'/>"/>

SOURCE NexBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
2. NexBio(R) Presents DAS181 (Fludase(R)*) Potently Inhibits Novel Swine-Origin A(H1N1) and NAI-Resistant Influenza Viruses, at ICAAC 2009
3. Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010
4. AAOS Clinical Guideline for Treating Spinal Compression Fractures Presents More Questions Than Answers for Medical Community
5. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
6. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
7. Spectros Presents New Clinical Studies Using T-Stat VLS Tissue Oximeter at Anesthesiology 2010
8. Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine
9. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
10. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
11. Caligor Rx Presents Penn and USciences Bioethicist at the 2010 Clinical Trial Supply East Coast Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... In accordance with Rule 17.1 and Rule 2.9 ... United States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") ... (NYSE: ELN). Background On 2 May ... for the entire of the issued and to be issued ... On 20 May 2013, Royalty Pharma announced ...
(Date:5/24/2013)... The potential of the pulmonary route as ... has been receiving undeniable attention with the recent advances ... crucial formulation considerations for orally inhaled products together with ... in the efficiency of pulmonary delivery, and great strides ... techniques and devices in recent years. With ...
(Date:5/23/2013)... , May 24, 2013 3SBio ... the "Company"), a leading China ... and marketing biopharmaceutical products, announced today that, at ... the Company,s shareholders voted in favor of the ... agreement and plan of merger dated February 8, ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... a clinico-molecular informatics company, today announced the commercialization ... lines that translate patient-specific molecular and genomic data, ... more effective drug choices for patients. ... drastically and clinical data becoming increasingly accessible, today,s ...
... /PR Newswire-Asia/ -- Global Pharm Holdings Group, Inc. ... growing vertically integrated pharmaceutical company engaged in the ... processing, and herbal cultivation and sales in China ... Shandong provinces, today announced the appointment of Mr. ...
Cached Medicine Technology:MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 2MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 3Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 3
(Date:5/25/2013)... 25, 2013 Pradaxa lawsuits ... episodes of internal bleeding while using the blood thinner continue ... Court, Southern District of Illinois, Bernstein Liebhard LLP reports. ... side effect claims had been filed in the ... 705 claims reported by the Court on May 15th. ( ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 On May ... brain cancer research and advocacy, comments on a new ... that shows incorporating cold atmospheric plasma into brain cancer ... , According to a Science Daily article, ... (MPE), biologists and physicians demonstrated the “synergistic effect of ...
(Date:5/25/2013)... Dr. Farooq Ashraf, founder of the Atlanta Vision ... his practice’s adoption of The iFS Advanced Femtosecond Laser. ... proven with more than 10 years of clinical research ... “We are happy to announce that we will now ... LASIK practice,” Ashraf said Thursday. “We have been using ...
(Date:5/25/2013)... The Slim Weight Patch has been clinically proven many ... to the highly sought after ingredients that have been used ... extra 2 months supply & premium membership of Slimming+ to ... you desire faster than ever. , Click Here to ... weight patch consumers can observe instant results within only a ...
(Date:5/25/2013)... For college students, few events ... they are turning to prescription stimulants like Adderall ... more on this, go to http://www.sciencedaily.com/releases/2013/05/130501145151.htm . ... that students who pick up Adderall, “just to ... developing a physical and psychological dependency. While initially ...
Breaking Medicine News(10 mins):Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2
... 12 Quest Diagnostics Incorporated (NYSE: DGX ... and services, announced today that it will report fourth-quarter ... for 2009 on Monday, January 26, before the market ... investors to discuss the results beginning at 8:30 a.m. ...
... Lilly and Company,(NYSE: LLY ) today filed ... (SEC) detailing the pro forma impact of the company,s ... available on the,SEC,s website at www.sec.gov and ... www.investor.lilly.com . , The content ...
... VANCOUVER, Jan. 12 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI ... million for the quarter and $141.9 million for the full ... quarter declined by 32.7% over the same quarter in 2007 ... annual sales in 2007. Sales in the U.S. for the ...
... Ranir, LLC, a leading,consumer products oral care company, ... foremost manufacturer and marketer of interdental oral,care products ... San Diego,California, Placontrol is the founder of the ... disclosed. , Ranir, headquartered ...
... Genomma Lab Internacional,S.A.B. de C.V. (BMV: LAB) ("Genomma ... the Company signed an agreement with IXE Casa de ... for the Company,s outstanding shares, thus,becoming another company to ... valid upon approval of the Mexican Stock Exchange (Bolsa,Mexicana ...
... has negative impact- No similar material exposures are expected ... wins are strong; service revenue expected to increase by ... Corporation (Nasdaq: PRXL ) has received notification ... unable to continue to make payments that are due ...
Cached Medicine News:Health News:Quest Diagnostics to Release Fourth Quarter and Full Year 2008 Financial Results 2Health News:QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2008 2Health News:Ranir, LLC Announces the Acquisition of Placontrol, Inc. 2Health News:Genomma Lab, New Participant in Market-Maker Program 2Health News:PAREXEL Reports Preliminary Second Quarter Results 2Health News:PAREXEL Reports Preliminary Second Quarter Results 3Health News:PAREXEL Reports Preliminary Second Quarter Results 4Health News:PAREXEL Reports Preliminary Second Quarter Results 5Health News:PAREXEL Reports Preliminary Second Quarter Results 6
The OneTouch Flexx Professional Blood Glucose Monitoring System with OneTouchPro Test Strips sets the standard for safety and convenience with unique off-meter sample application and a wide range of ...
... the market in New Technology, the Arrow ... whole new first and only IABP system ... a physiologically based timing algorithm, WAVE, to ... accuracy. Second generation Automaticity provides for ...
... NEXES Special Stains automated system ... to provide enhanced consistency of ... stains. Proprietary kinetic technology, including ... Mixing, assures high quality routine ...
... NexES IHC, the worlds first ... staining system introduced a whole ... while combining system modularity and ... laboratory productivity. The NexES Systems ...
Medicine Products: